Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

By sjmartinez • February 23, 2025

Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Feb 21;194:98-104. doi: 10.1016/j.ygyno.2025.02.013. Epub ahead of print. PMID: 39985870.

Tags: Endometrial cancer, Hematology/Oncology, Platinum-free interval, Publications

Evaluating the feasibility and efficacy of exercise interventions for older survivors of cancer

Ji J, Niknafs A, Jones LW. Evaluating the feasibility and efficacy of exercise interventions for older survivors of cancer. Cancer. 2026 Mar 1;132(5):e70278. doi: 10.1002/cncr.70278.[...]

A Review of Patient-Reported Outcomes and Clinical Outcomes in Acute and Chronic Myeloid and Lymphoid Leukemias

Chan B, Balar E, Villalona S, Karp J, Leahy A, Lai C. A Review of Patient-Reported Outcomes and Clinical Outcomes in Acute and Chronic Myeloid[...]

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

Rodriguez GE, Zhao Y, Nishiga Y, Peprah F, Shen J, Abhiraman GC, Ogishi M, Zhang C, Saco J, Waghray D, Serasanambati M, Torres L, Simone[...]